SIC
MLYS icon

SJS Investment Consulting’s Mineralys Therapeutics MLYS Stock Holding History

SJS Investment Consulting’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324 Hold
12
– – ﹤0.01% 2379
2026
Q1 		$326 Buy
+12
New +$352 ﹤0.01% 1874

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

SJS Investment Consulting's MLYS Position: Q2 2026 in Review

SJS Investment Consulting held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 12 shares worth $324. The position accounts for ﹤0.01% of the portfolio, ranked #2379.

SJS Investment Consulting first reported a position in MLYS in Q1 2026 and has held it in 2 quarters since. The position peaked at $326 in Q1 2026. 95 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • SJS Investment Consulting held 12 shares of Mineralys Therapeutics worth $324 as of Q2 2026.
  • SJS Investment Consulting left its Mineralys Therapeutics share count unchanged in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2379 holding.
  • SJS Investment Consulting first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • SJS Investment Consulting's Mineralys Therapeutics position peaked at $326 in Q1 2026.
  • 95 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.